22nd Century Group (NASDAQ:XXII – Get Free Report) posted its earnings results on Monday. The biotechnology company reported ($247.80) earnings per share for the quarter, missing the consensus estimate of ($174.00) by ($73.80), FiscalAI reports. The company had revenue of $4.76 million during the quarter, compared to analyst estimates of $8.42 million. 22nd Century Group had a negative net margin of 79.97% and a negative return on equity of 62.74%. During the same quarter last year, the business posted ($0.28) EPS.
Here are the key takeaways from 22nd Century Group’s conference call:
- Third-quarter revenue rose 66% sequentially to $4.8 million, and gross profit turned positive at $0.4 million; the operating and adjusted EBITDA losses also narrowed. Management attributed the improvement to better product mix and pricing.
- Retail same-store sales for Pinnacle Pure and Pinnacle VLN reportedly increased 166% from the prior quarter, and the company is targeting wider retailer distribution and a fourth-quarter Gopuff launch. However, VLN cigarette revenue was still just $30,000 in the quarter, so branded-product sales remain at an early stage.
- Nine-month revenue fell to $11.7 million from $14.1 million a year earlier as the company exited lower-margin contract business. Operating expenses were higher year over year due to commercial investments, while the company continued to report operating and adjusted EBITDA losses.
- After raising about $5.8 million through its at-the-market facility and redeeming $1.2 million of Series B preferred shares, the company said it had approximately $8 million in pro forma cash, no debt, and runway into 2027 under its current outlook. All common-stock warrants have been eliminated, though the financing involved share issuance.
22nd Century Group Stock Down 11.4%
22nd Century Group stock opened at $0.44 on Wednesday. 22nd Century Group has a 52-week low of $0.42 and a 52-week high of $20,314.50. The company has a current ratio of 2.61, a quick ratio of 1.90 and a debt-to-equity ratio of 0.02. The company’s 50 day moving average is $43.70 and its two-hundred day moving average is $1,575.44.
Analysts Set New Price Targets
Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of 22nd Century Group in a research report on Monday, October 26th. One analyst has rated the stock with a Sell rating. According to MarketBeat, the stock presently has an average rating of “Sell”.
View Our Latest Analysis on 22nd Century Group
22nd Century Group Company Profile
22nd Century Group is a U.S. plant biotechnology and tobacco company known for developing tobacco with substantially reduced nicotine content. Its work has used plant breeding and genetic technologies to alter the nicotine profile of tobacco plants. The company’s best-known product is VLN, a line of reduced-nicotine cigarettes. In 2021, the U.S. Food and Drug Administration authorized VLN cigarettes to be marketed with a modified-risk claim stating that they contain substantially less nicotine than conventional cigarettes.
Featured Stories
- Five stocks we like better than 22nd Century Group
- Disney Has the Magic Touch: Dividend Growth and Buybacks Could Fuel a Breakout
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
Receive News & Ratings for 22nd Century Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 22nd Century Group and related companies with MarketBeat.com's FREE daily email newsletter.
